Full genetic architecture of RAS cancer gene mutations in human tumors uncovered

Study uncovers source of genetic variation influencing childhood brain tumors

Researchers at Baylor College of Medicine and collaborating institutions investigated for the first time in cancer the association between two sources of genetic variation: germline or inherited structural variation, which refers to large differences in the DNA sequence, and DNA methylation, which is when genes are turned on or off without altering the DNA code.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

A Johns Hopkins Medicine-led research team has identified a recurrent frameshift mutation, called F722fs, in the MMS22L gene among men of Ashkenazi Jewish ancestry that is associated with a higher risk of prostate cancer and increased sensitivity to a specific anticancer therapy.

May 23, 2025

Vol.51 No.20

Clinical

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.

Diane Reidy-Lagunes appointed chief of medical oncology at Duke

Diane Reidy-Lagunes joined Duke University School of Medicine’s Department of Medicine as chief of the Division of Medical Oncology, effective April 1.

May 02, 2025

Vol.51 No.17

In Brief

Swim Across America grants $900,000 toward gene editing innovation

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies.

April 25, 2025

Vol.51 No.16

Clinical Roundup

Researchers identify “master regulator” gene that could lead to more effective ovarian cancer treatment

Researchers have identified a “master regulator” gene, ZNFX1, that may act as a biomarker to help guide treatment in future clinical trials involving patients with therapy-resistant ovarian cancer, according to a study recently published in Cancer Research.

April 04, 2025

Vol.51 No.13

Full genetic architecture of RAS cancer gene mutations in human tumors uncovered

YOU MAY BE INTERESTED IN

Study uncovers source of genetic variation influencing childhood brain tumors

Genetic mutation in some Ashkenazi Jewish men may be linked to higher prostate cancer risk, study shows

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Diane Reidy-Lagunes appointed chief of medical oncology at Duke

Swim Across America grants $900,000 toward gene editing innovation

Researchers identify “master regulator” gene that could lead to more effective ovarian cancer treatment

Renew today!

Subscriber content

Never miss an issue!

Login